Latest Dopamine agonists Stories
SOUTH SAN FRANCISCO, Calif., July 26 /PRNewswire-FirstCall/ -- Titan Pharmaceuticals, Inc.
NEW YORK, July 8 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research today announced $1.1 million in total funding to six different projects aimed at validating potential therapeutic targets for Parkinson's disease.
It's a common scenario: you're on a diet, determined to give up eating cakes, but as you pass the cake counter, all resolve disappears.
BRUSSELS, June 18 /PRNewswire-FirstCall/ -- The first data to show that NeuproÂ® (rotigotine transdermal system) significantly improved wellbeing and daily activities that are often impaired by pain related to Restless Legs Syndrome (RLS) were presented this week at the 14th International Congress of Parkinson's Disease and Movement Disorders in Buenos Aires, Argentina.
A fast, simple and non invasive test of the ability to smell may be an important tool to screen people who are likely to develop Parkinson's disease (PD), in which motor symptoms only become evident at a later stage of the disease.
NESS ZIONA, Israel, June 1, 2010 /PRNewswire/ -- NeuroDerm, Ltd. announced today the successful enrollment and dosing in its Phase I clinical trial of ND0611.
A new study from Karolinska Institutet presents a new technique that makes drug testing possible through exhaled air for the first time.
WALTHAM, Mass., May 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that while levodopa remains the gold standard for Parkinson's disease treatment, physicians say they will increasingly use other agents to delay the need for levodopa.
Pathological gambling, compulsive shopping, binge eating and other impulse control disorders appear to be more common among individuals taking dopamine agonist medications for Parkinson's disease.
LAWRENCEVILLE, N.J., April 26 /PRNewswire/ -- Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced that it has acquired the U.S. marketing rights to LODOSYNÂ® (carbidopa) tablets from Bristol-Myers Squibb Company (BMS).
- To swell, as grain or wood with water.